新型及研究中的抗逆转录病毒药物的药物相互作用。
Drug interactions with new and investigational antiretrovirals.
作者信息
Brown Kevin C, Paul Sunita, Kashuba Angela D M
机构信息
School of Pharmacy, Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
出版信息
Clin Pharmacokinet. 2009;48(4):211-41. doi: 10.2165/00003088-200948040-00001.
More than 20 individual and fixed-dose combinations of antiretrovirals are approved for the treatment of human immunodeficiency virus (HIV) infection. However, owing to the ongoing limitations of drug resistance and adverse effects, new treatment options are still required. A number of promising new agents in existing or new drug classes are in development or have recently been approved by the US FDA. Since these agents will be used in combination with other new and existing antiretrovirals, understanding the potential for drug interactions between these compounds is critical to their appropriate use. This article summarizes the drug interaction potential of new and investigational protease inhibitors (darunavir), non-nucleoside reverse transcriptase inhibitors (etravirine and rilpivirine), chemokine receptor antagonists (maraviroc, vicriviroc and INCB 9471), integrase inhibitors (raltegravir and elvitegravir) and maturation inhibitors (bevirimat).
超过20种抗逆转录病毒药物的单一制剂和固定剂量组合已被批准用于治疗人类免疫缺陷病毒（HIV）感染。然而，由于耐药性和不良反应的持续存在，仍需要新的治疗选择。现有或新药类别中的一些有前景的新药物正在研发中，或最近已获得美国食品药品监督管理局（FDA）的批准。由于这些药物将与其他新的和现有的抗逆转录病毒药物联合使用，了解这些化合物之间药物相互作用的可能性对于它们的合理使用至关重要。本文总结了新型和研究性蛋白酶抑制剂（地瑞那韦）、非核苷类逆转录酶抑制剂（依曲韦林和利匹韦林）、趋化因子受体拮抗剂（马拉维若、维克维若和INCB 9471）、整合酶抑制剂（拉替拉韦和埃替拉韦）以及成熟抑制剂（贝维拉马特）的药物相互作用可能性。
Zotero 插件